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score. Results: Mean DMC per QoL was lowest in Pr, and highest in Hem cancers 
(ranged 60.1-195.1 TL/global QoL score) (Pr< Gy< CR≈Gas≈Br≈Lng≈H&N< Hem). QoL 
was lowest in Gy and highest in CR (ranged 53,1-65,2) (Gy< Lng< Pr< Br≈Hem≈H&NC). 
Total DMC ranged from 3124-13557 TL (Pr≈GY< Br< Gas≈CR< Lng≈H&N< Hem). 
Depending on the type of the cancer the association between DMC and QoL could 
be in different directions (the correlation between DMC and role functioning was 
positive in Gas, while it was negative in H&N cancer). ConClusions: For a fixed 
period of time the total DMC associated with the management of different types of 
cancers vary substantially. As expected the total cost does not however purchase 
equal amount of QoL for each type of cancer. For those cancers with higher DMC 
per QoL, we should consider implementing wider psychosocial support measures. 
Depending on the type of cancer DMC may reflect disease progression leading to 
decreased QoL, or it may reflect presence of an effective and aggressive manage-
ment leading to increased QoL.
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objeCtives: To evaluate the cost effectiveness of Pertuzumab plus Trastuzumab 
and docetaxel (PTD) vs. Trastuzumab and docetaxel (TD) for the first-line treat-
ment in patients with HER2+ metastatic breast cancer in Colombia. Methods: For 
the evaluation of the cost-effectiveness a health economic area under the curve 
model was developed. The model considers three health states: progression-free 
survival, disease progression and death. The proportion of patients in each health 
state were derived using patient level data from the CLEOPATRA trial like efficacy 
and safety results, with the exception where overall survival (OS) utilized data from 
longer term clinical registries. The primary model outcome is the ICER cost per QALY 
gained in the first-line PTD vs. TD. The following main model input data assump-
tions were applied for the base case analysis: Time horizon: 15 years; model cycle 
length: weekly; 3) reference prices for drugs in Colombia, except for Pertuzumab 
which was supplied by the manufacturer; 4) treatment duration: actual treatment 
duration from the CLEOPATRA study extrapolated using an exponential function; 
and 5) discount rates: annual rate of 3.0% for both, future costs and health ben-
efits. Results: The outcomes over a time horizon show an increase in mean OS 
time for patients assigned to the PTD group as compared to those in the TD of 0.72 
years. Mean QALYs are also higher in the PTD group than in the TD group 0.58 QALYs. 
The addition of Pertuzumab leads to higher total average treatment costs of $143.529 
dollars per patient compared to the TD group. These findings result in an ICER of 
$200.509 per life year gained and of $249.582 per QALY gained. ConClusions: 
When compared to commonly accepted cost-effectiveness thresholds, these results 
exceed commonly applied willingness-to-pay thresholds, but Pertuzumab becomes 
a therapeutic alternative that offers a better health outcome.
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objeCtives: To assess the cost-effectiveness of ipilimumab compared to dac-
arbazine as first-line treatment in patients with advanced metastatic mela-
noma. Methods: A three-state Markov (progression-free, progression and death) 
with three-week cycles model using the Spanish Healthcare System perspective was 
developed over a lifetime horizon. The clinical profile of ipilimumab (3 mg/kg) was 
obtained from a pooled dataset of chemotherapy naive patients from four phase 
II and phase III studies, and from the CA184-024 trial for dacarbazine. Parametric 
extrapolation methods were used to project survival over lifetime. Costs included 
were: drug acquisition (ex-factory price -7,5% mandatory rebate) and administra-
tion, medical/terminal care, and adverse events management. Unit costs were 
derived from Spanish health care cost databases (Euros, 2013). For drugs with a 
double-pricing system (like ipilimumab), costs were based upon the official noti-
fied prices in Spain. Costs and benefits were discounted at 3%. Utility values were 
taken from the CA184-024 trial. Univariate and probabilistic sensitivity analyses 
(PSA) were performed. Results: The life years (LYs) and quality-adjusted life years 
(QALYs) gained with ipilimumab as first-line treatment over dacarbazine were 2.01 
and 1.68, respectively. The incremental cost of using ipilimumab versus dacarbazine 
was 69,598 € . The incremental cost-effectiveness ratio (ICER) and the incremental 
cost-utility ratio (ICUR) were 34,566€ /LY gained and 41,459€ /QALY, respectively. PSA 
showed that ipilimumab is up to 100% and 90% likely to be cost-effective at the 
threshold established by the NICE for oncology drugs that meet ‘End-of-Life’ crite-
ria (50,000-62,000€ ) for ICER and ICUR, respectively. Additionally, at the threshold 
acceptable in Spain (30,000-45,000€ ) the likelihood of ipilimumab being cost-effec-
tive is up to 94% and 66% for ICER and ICUR, respectively. ConClusions: Results 
suggest that ipilimumab is a cost-effective alternative for previously untreated 
patients with advanced metastatic melanomain Spain.
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objeCtives: MR colonography may have potential as a colorectal cancer (CRC) 
screening tool since it has comparable test characteristics as colonoscopy but 
is less invasive. Furthermore, innovators in the field of MR technology are striv-
tests) were based on official reimbursed prices. Results: Out of 4,934 newly diag-
nosed breast cancer women, 27.5% (1,357) were appropriate for the test application. 
Only 35% of the women undertaken the oncotype test (N= 1,357) were found as high 
risk for recurrence (N= 475). The average total cost of chemotherapy treatment was 
estimated to € 8,271 from which more than 80% refer to pharmaceuticals. The total 
treatment cost for women who didn’t undertake the test reached to € 10.9 mil., 
while the relevant cost for women who undertook the test was estimated to € 8 mil.  
ConClusions: The introduction of Oncotype DX® to the Greek health care system 
had as a result annual cost savings of almost € 3 million and avoidance of unneces-
sary chemotherapy treatment (and associated complications) to more than 880 
women.
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objeCtives: The degree of benefit from colonoscopy in the prevention of colorectal 
cancer (CRC) is highly dependent on the quality of bowel cleansing. In a rand-
omized study of patients undergoing screening colonoscopy in Germany (MODEC), 
2L polyethylene glycol with electrolytes + ascorbate components (PEG+ASC) resulted 
in numerically higher overall polyp/adenoma detection rates (PDR/ADR) and sig-
nificantly higher right-sided PDR/ADR than sodium picosulfate/magnesium citrate 
(NaPic/MgCit), together with better bowel cleansing. The objective of the model 
was to examine the socioeconomic impact of bowel cleansing quality on the effec-
tiveness of CRC screening in the eligible German population. Methods: A cost-
consequence model was constructed to compare the total cost of colonoscopy and 
treatment of subsequent CRC over a 10-year period in a cohort of 10,000 patients 
aged ≥ 55 years receiving 2L PEG+ASC or NaPic/MgCit prior to colonoscopy. The 
rates of successful bowel cleansing, completed colonoscopies, and PDR/ADR were 
obtained from the MODEC study. Published rates of surveillance colonoscopy, associ-
ated costs and health care resource utilization in Germany were used, with costs 
inflated to 2013 prices. Results: The model predicts that the use of 2L PEG+ASC 
versus NaPic/MgCit increases the average per patient cost associated with colonos-
copy by € 67. However, better bowel cleansing and numerically higher overall PDR/
ADR achieved using 2L PEG+ASC rather than NaPic/MgCit avoids progression to CRC 
in 166 patients, due to early detection, equating to an average per patient saving in 
CRC treatment costs of € 488. The model shows that the use of 2L PEG+ASC versus 
NaPic/MgCit at screening/surveillance colonoscopy leads to an average overall cost 
saving of € 420 per patient over 10 years. ConClusions: Modeling of long-term 
outcomes shows that using an effective bowel cleansing preparation in CRC screen-
ing may reduce the number of patients developing CRC, and may lead to reduced 
CRC treatment costs.
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objeCtives: The objective of the study was to estimate the potential cost and epi-
demiological impact of a Human Papillomavirus (HPV) mass vaccination in Romania 
for the two available vaccines in the Romania: AS04 adjuvanted HPV16/18 vac-
cine (AS04V) and the HPV6/11/16/18 vaccine (QV). Methods: We applied, to the 
Romanian settings, a population steady state model previously published with a 
one year time horizon estimating the effect (cases and costs) of a vaccination pro-
gramme. The number of cases and costs (in RON – Romanian National Currency) 
were collected from the hospitalization Diagnosis Related Group database for the 
year 2012. cervical cancer (CC) and genital warts (GW) were considered. Vaccine 
effectiveness was approximated by weighting vaccine-type and non-vaccine-type 
efficacy with HPV distribution reported for GW (literature) and CC (HPV Centre) for 
each vaccine. One way sensitivity analysis was conducted on key input param-
eters. Results: HPV vaccination would save17,706,490 RON with AS04V and 
16,432,592 RON with QV. An additional 820 CC-related hospitalisations amounting 
to a cost difference of 1,273,898 RON was estimated in favour of the AS04V. A total 
of 205 cases of GW prevented and 153,395 RON associated costs were estimated in 
favour of the QV. The total cost difference amounted to 1,120,503 RON. Robustness of 
the results was confirmed by sensitivity analyses”. ConClusions: Implementing 
the AS04V would result in > 1 million RON saved versus the QV mainly due to a dif-
ference of extra 820 CC cases prevented that completely offsets the benefit associ-
ated with the prevention of GW. The observed difference is mainly due to higher 
protection associated with non-vaccine types for AS04V.
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objeCtives: The new cancer treatment modalities are improving survival rates 
today and one of the main outcomes is the improved health related quality of 
life (QoL). Prolonged survival also increases the financial burden of cancer care on 
health care systems. In this study we aimed to analyze the associations between 
QoL and direct health care costs in different types of cancers. Methods: We evalu-
ated QoL (EORTC QLQ-C30) and direct medical costs (DMC) in 350 patients with lung 
(Lng), breast (Br), hematological (Hem), head and neck (H&N), colorectal (CR), gastric 
(Gas), gynecological (Gy), and prostate (Pr) cancers. The DMC data of each patient in 
the following 3-month period after QoL assessment was obtained from the hospi-
tal finance department database. DMC per QoL point was calculated by DMC/QoL 
